Health Market Developments & Director Resig...

Byotrol plc
                  

Byotrol plc

23 March 2006

Developments in Healthcare Market and Resignation of Director

Byotrol plc ('the Company') is pleased to announce some important developments
in the health sector - a key market for the Company's microbial control
products.

As set out in the announcement of interim results for the period ended 30
September 2005, the Company is undertaking a trial with a major NHS hospital to
study the efficacy of its technology in reducing the spread of hospital-acquired
MRSA. The initial phase is complete with encouraging preliminary results that
show significantly reduced environmental MRSA. Given these preliminary results,
the Company is now seeking to extend the scope of the trial to assess the
effectiveness of Byotrol's products across a wider range of operational clinical
environments.

Preparatory work is underway for presentation of the results at a major
Infection Control meeting within the healthcare industry in the third quarter of
2006. The Directors believe that a key commercial advantage of Byotrol's product
range is the ability to integrate with the existing hygiene regime without
requiring capital investment, special safety measures or significant staff
training, patient relocation or otherwise disrupting the day-to-day working of
the clinical environment.

The Company has also recently launched a range of hygiene products in
conjunction with Quill International Industries plc ('Quill'), aimed at the
Health market segment. These hygiene products include disposable wipes, hand
sanitisers and cleaners. They are being marketed in the UK on a non-exclusive
basis by Quill under the name 'Supernova' (a registered trademark of Quill) but
with the Byotrol logo displayed on the label in line with Company's ingredient
branding approach. Quill has an established customer base in the healthcare
sector including the National Blood Service and Sunlight Service Group. Byotrol
is also marketing the range direct to international customers and through
selected UK distributors.

In addition, Byotrol has developed a range of sanitization and deodorisation
products specifically designed to combat the spread of micro-organisms in care
homes.

These products are being marketed under the name 'assure', which the Company is
seeking to register as a trademark. The product launch at 'The Healthcare Event
2006', Europe's leading conference and exhibition for the care homes sector, in
January was well received and several major companies including CareTech, which
has 61 homes across the UK as well as Care UK, Pilgrim Homes and Caring Homes
have all indicated a willingness to trial the assure range from April 2006.

Now that these and other opportunities have been significantly progressed and
the Company has completed its move from a research and development phase to the
commercialisation phase, the Company also announces the resignation of Dr Peter
Dandalides from the Board with immediate effect. The Board thanks Dr Dandalides
for the valuable role he has played in developing the Company's medical and
scientific credentials and establishing the initial market opportunities for
Byotrol's products in this sector including those set out above. Dr Dandalides
leaves the Company to pursue other opportunities in his specialist scientific
field although he has agreed to continue to assist the Company on specific
projects in a consultancy capacity in the short term.

Financial calls to:
Stephen Falder
Byotrol plc
0870 609 4480

Or

Oli Rayner
Merchant Capital
0207 332 2200

Media calls to
Jim Rothnie
McCann Erickson
T: 01625 822540
M: 07836 559305
E:[e-mail]